1.Refined correction method of unilateral cleft lip nasal deformity.
Yeon Chul JUNG ; jin Hwan KIM ; Rong Min BAEK ; Kab Sung OH ; Se Min BAEK
Journal of the Korean Society of Plastic and Reconstructive Surgeons 1993;20(5):1006-1013
No abstract available.
Cleft Lip*
;
Congenital Abnormalities*
2.Effects of Phospholipase A2 Inhibitor, Ochnaflavone, on the TNF-alpha and NO Production in Macrophages.
Jung Hee KIM ; Chul JIN ; Jung Gil HONG ; Pan Gil SEO ; Suk Hwan BAEK
Korean Journal of Immunology 2000;22(3):157-163
No abstract available.
Macrophages*
;
Phospholipases A2*
;
Phospholipases*
;
Tumor Necrosis Factor-alpha*
3.Recent Advances in Core Needle Biopsy for Thyroid Nodules.
Chan Kwon JUNG ; Jung Hwan BAEK
Endocrinology and Metabolism 2017;32(4):407-412
Core needle biopsy (CNB) was introduced as an alternative diagnostic tool to fine-needle aspiration (FNA), and is increasingly being used in the preoperative assessment of thyroid nodules. CNB provides a definitive diagnosis in most cases, but it sometimes may be inconclusive. CNB has the advantage of enabling a histologic examination in relation to the surrounding thyroid tissue, immunohistochemistry, and molecular testing that can provide a more accurate assessment than FNA in selected cases. Nevertheless, CNB should be performed only by experienced experts in thyroid interventions to prevent complications because CNB needles are larger in caliber than FNA needles. As recent evidence has accumulated, and with improvements in the technique and devices for thyroid CNB, the Korean Society of Thyroid Radiology released its 2016 thyroid CNB guidelines and the Korean Endocrine Pathology Thyroid Core Needle Biopsy Study Group published a consensus statement on the pathology reporting system for thyroid CNB in 2015. This review presents the current consensus and recommendations regarding thyroid CNB, focusing on indications, complications, and pathologic classification and reporting.
Biopsy, Fine-Needle
;
Biopsy, Large-Core Needle*
;
Biopsy, Needle
;
Classification
;
Consensus
;
Diagnosis
;
Immunohistochemistry
;
Needles
;
Pathology
;
Thyroid Gland*
;
Thyroid Nodule*
6.Long-Term Outcomes Following Thermal Ablation of Benign Thyroid Nodules as an Alternative to Surgery: The Importance of Controlling Regrowth
Endocrinology and Metabolism 2019;34(2):117-123
Thermal ablation (TA) procedures, such as radiofrequency ablation and laser ablation, are used for the treatment of benign thyroid nodules. Short-term studies (<2 years) have demonstrated that TA is an effective and safe procedure to improve cosmetic or symptomatic problems. However, studies including a longer follow-up period show that treated thyroid nodules can increase in size after 2 to 3 years. Several studies suggest that this results from regrowth at the undertreated nodule margins. Here, we review current data on regrowth after TA and describe factors related to it and possible approaches to prevent it.
Catheter Ablation
;
Follow-Up Studies
;
Laser Therapy
;
Thyroid Gland
;
Thyroid Nodule
7.Response: Long-Term Outcomes Following Thermal Ablation of Benign Thyroid Nodules as an Alternative to Surgery: The Importance of Controlling Regrowth (Endocrinol Metab 2019;34:117–23, Jung Suk Sim et al.)
Endocrinology and Metabolism 2019;34(3):325-326
No abstract available.
Thyroid Gland
;
Thyroid Nodule
9.Forehead augmentation with hydroxyapatite.
Yeon Chul JUNG ; Jae Hyun PARK ; Jin Hwan KIM ; Rong Min BAEK ; Kap Sung OH ; Se Min BAEK
Journal of the Korean Society of Plastic and Reconstructive Surgeons 1993;20(5):1039-1048
No abstract available.
Durapatite*
;
Forehead*
10.A Comparative Study of USA and Europe Guidelines of Rate and Rhythm Control Pharmacotherapy in Atrial Fibrillation.
Eun Joo JUNG ; KieHo SOHN ; In Hwan BAEK
Korean Journal of Clinical Pharmacy 2016;26(1):84-95
OBJECTIVE: Atrial fibrillation (AF) guidelines have been published in the USA and Europe. Recently, the USA and Europe have updated their guidelines, respectively. These new AF guidelines help in addressing key management issues in clinical situations. This study, therefore, systematically compared guidelines for rate and rhythm control pharmacotherapy of patients with AF between the USA (American College of Cardiology and American Heart Association, ACC/AHA) and Europe (European Society of Cardiology, ESC). METHODS: This study investigated and compared American guidelines (2014) and European guidelines (2010 and 2012). RESULTS: Generally, there are four meaningful differences between ACC/AHA and ESC guidelines. Important differences are treatment classification system, level of recommendation, drug list, and dosage. In addition, ACC/AHA described pharmacokinetic drug interactions for antiarrhythmic drugs. ESC emphasized ECG and atrioventricular nodal slowing as feature of antiarrhythmic drugs. CONCLUSION: This research addresses important use of anti-arrhythmic drugs and movement to accept recent recommendations in Korea. For the successful application of the guidelines, a role of pharmacists is crucial in clinical situation.
American Heart Association
;
Anti-Arrhythmia Agents
;
Atrial Fibrillation*
;
Cardiology
;
Classification
;
Drug Interactions
;
Drug Therapy*
;
Electrocardiography
;
Europe*
;
Humans
;
Korea
;
Pharmacists